The real-time monitoring of patients through medically integrated dispensing (MID) programs can reduce costs of care and remove barriers, said Christie Smith, PharmD, MBA, vice president, pharmacy and payer strategy, Cencora.
Medically integrated dispensing (MID) can help reduce cost of care through real-time monitoring of patients to address adverse effects in a timely manner, said Christie Smith, PharmD, MBA, vice president, pharmacy and payer strategy, Cencora.
In her session, Smith discussed innovative care models and MID programs. She was joined by Marci Conlin, vice president, pharmacy network management, Prime Therapeutics/Magellan Rx Management; and Kyle Verley, director, network management, Prime Therapeutics.
Transcript
How are innovative care models, such as MID programs, working to remove barriers to care and address disparities?
We are constantly working to help address SDOH, social determinants of health. Our providers are stretched all over the place, and so we try to support them in helping patients get the right resources to what they need, basic resources. I think that it is challenging. It is challenging. I think we need more nonprofit organizations to help not only physicians but payers. I think the payers need to provide some sort of financial support so that providers and the entire community can afford to help their patients in those ways.
What are innovative care models implementing to reduce costs of care?
So, for example, in the model that we're participating in, what plans have seen is that MID actually is a cheaper cost model than specialty pharmacy. I've worked for a specialty pharmacy in my lifetime. I love specialty pharmacy. But there are certain situations where it would make sense for certain therapies to be considered in this model. Basically, the total cost of care has been reduced under the [MID] model. And I think I sort of alluded to some examples like you can see in real time if a patient will or will not need the medication due to disease progression, side effect management from the cost of that drug.
That side effect management is so critical because this where, if a patient is having severe diarrhea, because that’s a common reaction, and they have to go to the hospital to get treated because of dehydration and all of that, that cost avoidance is huge for a medical plan vs when this script is outside of the practice’s direct authority.
Expanding Access to Gene Therapies: Addressing Patient Burden, High Costs
December 3rd 2024Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and utilization, explained Kevin Niehoff, PharmD, BCMAS, of IPD Analytics.
Read More
CMS, HHS Finalize Mandatory Model to Boost Kidney Transplant Access, Equity
December 2nd 2024The 6-year mandatory Increasing Organ Transplant Access Model aims to boost kidney transplants and address disparities by incentivizing hospitals, enhancing care coordination, and measuring transplant outcome performance.
Read More
Expert Insights on How Utilization Management Drives Physician Burnout
November 26th 2024On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.
Listen
sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS
November 29th 2024The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.
Read More